Inside the Trade: What Bill Ackman Sees in Valeant and Allergan

The Pershing Square activist has avoided investing in drugmakers before, but he and Valeant CEO Michael Pearson understand each other

2014-08-michael-peltz-upfront-inside-the-trade-small.jpg
2014-08-michael-peltz-upfront-inside-the-trade-article-page.jpg

When William Ackman took the stage at the AXA Equitable Auditorium in Midtown Manhattan on April 22, investors were still digesting the news that his firm, Pershing Square Capital Management, had amassed a 9.7

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related